CMMB Chemomab Therapeutics Ltd - ADR

$CMMB 🚨 CMMB SHAREHOLDERS — IT’S TIME TO ORGANIZE Chemomab’s market cap has fallen below $8M despite nebokitug’s potential in PSC, SSc and RA. Is this really the best outcome shareholders can achieve with the Scipher merger? We need to stop being passive and start asking serious questions. 📌 Should the Board reconsider the merger? 📌 Has every realistic pharma buyer and licensing partner been explored? 📌 Could separate PSC/SSc licensing deals and an RA collaboration with Scipher unlock more value? 📌 Should shareholders push for an independent investment bank to evaluate strategic alternatives? One shareholder speaking up can be ignored. Organized shareholders asking the same questions are harder to ignore. I’m looking to connect with fellow CMMB shareholders interested in a coordinated, lawful shareholder-advocacy effort to demand transparency, accountability, and a serious evaluation of alternatives that may better protect shareholder value.

$CMMB My Investment Rationale. Disclaimer: NOT FINANCIAL ADVICE. I am long $CMMB so consider my views to be biased.

$CMMB Letter sent to the board to explain to them the seriousness of this situation and the path they appear to be choosing. The fact that they are choosing to close in early 2027, which btw could be February for all we know, is pretty damning towards the fiducial responsibility of Chemomab Therapeutics board. Even here they are failing their shareholders. They could have closed in Q4 this year, in fact they have written Q4 close ever since July and the signing of the merger with Scipher and PIPE, but now suddenly they are pushing merger past that and in to 2027. Knowing very well that they have said on record that their cash will likely only last out March 2027. So they could be putting the company under jeopardy, in a merger process the market seems to have tossed in to the trash many months ago. Amendment to the PIPE or change of the restricted shares to force a Nasdaq compliance after a YES vote on the proxy in early December, could open them up for lawsuits from many shareholders.

$CMMB Here is undeniable facts about the merger partner: If you were Chemomab, would you merge with this company? If I bet I would wager that most of this was not available for Adi at the time of signing, which is why the finance part of Scipher was not ready for the S-4 when they sent it in for review. Do your own 2+2 regarding this: - Scipher is burning $44M in 2025. They will put in $30M that is suppose to give enough headroom for TWO companies, until 2028. Do you think that is actually true...? - Scipher have a $10M+ lawsuit pending. It is still active. - Scipher have already spent $10M of the pledged $30M on 2026 Notes - Scipher have a going concern and was pretty much out of cash when they approached Chemomab - Scipher had $200M + debt when they approached Chemomab. That is due in 2027 - Scipher had $750K in revenue in 2026, after a collapse from $10M in 2024 - The testing they boast to give better data for the Phase 2 trial for RA is therefor very limited and could be already outdated

$CMMB The drug has real value: two acquisition attempts and one partnership attempt. The fear of walking away from the merger is overblown. Company Date Description in the S-4 A Jan 9, 2024 Non-binding term sheet contemplating an option to acquire nebokitug (not a full acquisition). Discussions ended after Company A was acquired by a third party in September 2025. B Oct 11, 2024 Non-binding term sheet contemplating the acquisition of Chemomab Israel and continued development of nebokitug in PSC. C Dec 2025 – Mar 2026, then a "brief re-engagement" in June 2026 Negotiations on a "strategic transaction" for nebokitug in PSC. The type of deal is not specified (it may not have been an acquisition).

$CMMB Seeing a lot of FUD that Nasdaq will automatically reject the $CMMB/Scipher merger because CMMB is trading ~$1.2–1.4. That is NOT how the math works. Current estimated exchange ratio: 1 CMMB ADS ≈ 0.374 SCIP shares So the relevant price is the new SCIP share price, not CMMB’s current quote. Under Nasdaq’s standard $4 initial-listing route: $4 SCIP × 0.374 = ~$1.50 CMMB So CMMB around $1.50 mechanically corresponds to a $4 SCIP price.

$CMMB Scipher and its investors won't fix the $15 million market value problem until after a "yes" vote. The listing application has still not been announced, which suggests a high probability that it has not been filed, and I think they are waiting for the vote results.

$CMMB $ARTV For those out of the loop: Artiva had to discontinue their entire pipeline after their RA drug failed Phase 2 and there was some deaths to patients. They are now without a pipeline, and is seeking strategic opportunities. They have unlike going concern crappy Scipher Medicine, cash. $300M which was collected to develop RA. And they have expertize in clinical trials, looking to cut 95% of their workforce. They had RA and SSc in the pipeline. That is now dead. nebokitug from Chemomab Therapeutics have Phase 2 for RA soon, they have IND for SSc clear, they have Phase 3 alignment with FDA for PSC, with Orphan status and Fast Track designation. Artiva have the expertise to run trials, they can develop nebokitug, without firing the people. They have $300M cash and can run PSC. Its a match made in heaven. Artiva wants a new IP, Chemomab wants a partner. Leerink have run outreach for Chemomab in 2024, they now run Artiva`s search for a partner. This is perfect.

$CMMB trading at 80% discount to PIPE valuation currently... I get why... But I also could see it getting pumped eventually (assuming a timely merger closure...)

$CMMB The announced ratio is about 0.37 and may be adjusted before closing. If the company needs a price above $4 as a safety margin, it may lower it, which reduces the number of new shares. It could reach 0.25, meaning 4-to-1, or less. This would weaken the price further and they would enter a spiral. They would then collide with the $15 million minimum market value requirement. Why do these problems appear? Because the merger was not built on real investment foundations. It has other goals: accumulated debts and a deficit that eats away the assets, and this is clear in the S-4

$CMMB – Important merger progress! The definitive proxy (DEFM14A) was filed on October 30, with shareholder materials expected to be mailed around November 3 and the merger vote scheduled for December 4. This is significant because we have moved beyond the preliminary proxy stage. The September 25 S-4EF filing also points to the registration statement having already become effective. In other words, the merger is progressing through the formal shareholder approval process. My takeaway: The S-4 effectiveness and definitive proxy are tangible procedural milestones. However, this is not a done deal yet. The December 4 vote and, especially, Nasdaq listing clearance remain critical hurdles.

$CMMB very disappointing situation. Is there any hope? Why did two board members resign? Was there another viable solution or this was it?

$CMMB modifies its Domestication Merger Amendment to reduce the share count for the pending Chemomab-Scipher transaction.

$CMMB I am not trying to silence anyone. I mentioned in an earlier poast that I don't understand why nobody wants this moelcule but you seem to believe that it is a blockbuster, I can't argue, I'm no scientist, but let's face it, it doesn't add up. Therfore, how could you be so sure that this is an utter fiasco? And if so, answer why is ther support? OK, so they are being sent a lifeline with the PIPE in order to recover their invesment. Great! We need to keep a close eye on when they will manipulate the SP upwards and get out. I've seen this before, in one day the SP soared about 500%, maybe more, can't remeber, with milions of shares traded and dropped the following days to below the original SP. That's my strategy at this point

$CMMB With all the negativity on this board from the two only extra active posters who flipped 180 degrees form bullish to bearish, it surely doesn't help the SP. Also, I fail to understand that if this deal is as bad as the bears are stating, how did they get the support from key/major investors and PIPE funding...boggles my mind. It's like, we, the retail investors know more than the insiders!

$CMMB I am completely failed as a trader by investing in this trash Suffering from past 5 years and went through several reverse splits. Lost so much capital. My stress can't be explained enough. I recently bought few and lost another grand. Stock price less than $1.X is another blow to me. Completely fkked up.

Until the end of this month some results that could be interesting will be out, like $CMMB , $AMST , ARBB, $PW , in the microcap space.

$CMMB I long for the following: 15% — Probability of a better offer or alternative rescue: A slim margin contingent upon a sudden move or a strategic investor stepping in to rescue the assets.

$CMMB -Phase 2 RA Trial- -Fast- 140 pts. over 12 weeks -Cheaper-~$20 million -Defined endpoint-ACR20 the standard measure of clinical improvement in RA. -Patient selection could be contracted to Scipher. Was it necessary for CMMB to give Scipher shareholders control of the combined company to obtain financing and access to patient screening technology?

$CMMB Look at all these looooosers🤣🤣🤣🤣🤣🤣 Love to see you all are down at least 90% and so many others who blocked 🚫 me for telling the people truth. 🤣🤣🤣🤣🤣 U all are. f. Ck. ed. up. Cheers 🍻 👏 ✌️ 🥂 🍻 👏